Literature DB >> 24679127

Effectiveness of cognitive behavior therapy for severe mood disorders in an acute psychiatric naturalistic setting: a benchmarking study.

Thröstur Björgvinsson, Sarah J Kertz, Joseph S Bigda-Peyton, David H Rosmarin, Idan M Aderka, Edmund C Neuhaus.   

Abstract

The current study examined the effectiveness of brief cognitive behavior therapy (CBT) for severe mood disorders in an acute naturalistic setting. The sample included 951 individuals with either major depressive disorder (n = 857) or bipolar disorder with depressed mood (n = 94). Participants completed a battery of self-report measures assessing depression, overall well-being, and a range of secondary outcomes both before and after treatment. We found significant reductions in depressive symptoms, worry, self-harm, emotional lability, and substance abuse, as well as significant improvements in well-being and interpersonal relationships, post-treatment. Comparable to outpatient studies, 30% of the sample evidenced recovery from depression. Comparison of findings to benchmark studies indicated that, although the current sample started treatment with severe depressive symptoms and were in treatment for average of only 10 days, the overall magnitude of symptom improvement was similar to that of randomized controlled trials. Limitations of the study include a lack of control group, a limitation of most naturalistic studies. These findings indicate that interventions developed in controlled research settings on the efficacy of CBT can be transported to naturalistic, "real world" settings, and that brief CBT delivered in a partial hospital program is effective for many patients with severe depressive symptoms.

Entities:  

Keywords:  benchmarking study; cognitive behavioral therapy; depression; naturalistic setting; treatment outcome

Mesh:

Year:  2014        PMID: 24679127     DOI: 10.1080/16506073.2014.901988

Source DB:  PubMed          Journal:  Cogn Behav Ther        ISSN: 1650-6073


  7 in total

1.  Network analysis of depression and anxiety symptom relationships in a psychiatric sample.

Authors:  C Beard; A J Millner; M J C Forgeard; E I Fried; K J Hsu; M T Treadway; C V Leonard; S J Kertz; T Björgvinsson
Journal:  Psychol Med       Date:  2016-09-14       Impact factor: 7.723

2.  Total sleep time and kynurenine metabolism associated with mood symptom severity in bipolar disorder.

Authors:  Dahlia Mukherjee; Venkatesh Bassapa Krishnamurthy; Caitlin E Millett; Aubrey Reider; Adem Can; Maureen Groer; Dietmar Fuchs; Teodor T Postolache; Erika F H Saunders
Journal:  Bipolar Disord       Date:  2017-08-23       Impact factor: 6.744

3.  Interest in spiritually integrated psychotherapy among acute psychiatric patients.

Authors:  David H Rosmarin; Brent P Forester; Daniel M Shassian; Christian A Webb; Thröstur Björgvinsson
Journal:  J Consult Clin Psychol       Date:  2015-08-17

4.  The role of pretreatment outcome expectancies and cognitive-behavioral skills in symptom improvement in an acute psychiatric setting.

Authors:  Christian A Webb; Sarah J Kertz; Joe S Bigda-Peyton; Thröstur Björgvinsson
Journal:  J Affect Disord       Date:  2013-03-13       Impact factor: 4.839

5.  Transdiagnostic mechanisms in depression and anxiety: The role of rumination and attentional control.

Authors:  Kean J Hsu; Courtney Beard; Lara Rifkin; Daniel G Dillon; Diego A Pizzagalli; Thröstur Björgvinsson
Journal:  J Affect Disord       Date:  2015-08-28       Impact factor: 4.839

6.  Dampening of Positive Affect Predicts Substance Use During Partial Hospitalization.

Authors:  Andrew D Peckham; R Kathryn McHugh; Elizabeth T Kneeland; Thröstur Björgvinsson; Courtney Beard
Journal:  Cognit Ther Res       Date:  2020-04-17

7.  Network analysis of depressive and anxiety symptoms in adolescents during and after the COVID-19 outbreak peak.

Authors:  Rui Liu; Xu Chen; Han Qi; Yuan Feng; Zhaohui Su; Teris Cheung; Todd Jackson; Hui Lei; Ling Zhang; Yu-Tao Xiang
Journal:  J Affect Disord       Date:  2022-01-04       Impact factor: 4.839

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.